Business Context and Reporting Period
This Form 8-K is a current report filed by MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD) on November 12, 2021. The filing addresses corporate governance matters regarding the scheduling of the 2021 Annual Meeting of Stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to procedural updates regarding shareholder meetings and does not contain financial performance data.
Material Changes
The primary material change reported is the rescheduling of the 2021 Annual Meeting of Stockholders. The Board of Directors established December 29, 2021, as the new meeting date, replacing the previously anticipated timeline. This change exceeds 30 days from the anniversary of the 2020 Annual Meeting, triggering specific disclosure requirements for shareholder proposals.
Guidance, Outlook, and Management Commentary
Management commentary is limited to the procedural update regarding the Annual Meeting. The filing specifies that the deadline for receipt of stockholder proposals or nominations for inclusion in the proxy statement pursuant to Rule 14a-8 is November 22, 2021, at 5:00 p.m. Eastern Time. No financial guidance, risk factors, or contingencies are discussed in this document.
Key Facts for Investor Verification
- Annual Meeting Date: December 29, 2021.
- Record Date: November 8, 2021 (previously established).
- Proposal Deadline: November 22, 2021, at 5:00 p.m. Eastern Time for Rule 14a-8 submissions.
- Reason for Filing: The meeting date change exceeded 30 days from the prior year's anniversary, necessitating the disclosure of the proposal deadline.